Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DIABET IR IDI-20080283 | Other Identifier | VEGENAT, S.A. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus Diabet IR).
The main objective of this project is to evaluate blood glucose metabolic control, insulin requirements, insulin action resistance, lipid profile and to reduce infectious complications on mechanical ventilation ICU (intensive care unit) patients after the administration of a complete diet enriched in MUFA and slow absorption carbohydrates, without fructose.
Enteral formula administration designed for critically ill patients in metabolic stress situations, hyperglycemia and insulin resistance, formulated with monounsaturated fatty acids (MUFA), slowly absorption carbohydrates, omega-3 series polyunsaturated fatty acids (PUFA)enriched in eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), should be associated with an improvement in metabolic control, based on glucose levels reduction, and a decrease of insulin resistance infectious complications , mechanical ventilation days, ICU and hospital stay. All this against other two high protein conventional specific diets for hyperglycaemia patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T-DIET PLUS DIABET IR | Experimental | Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric |
|
| ISOSOURCE PROTEIN FIBRE | Active Comparator | Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric |
|
| GLUCERNA SELECT | Active Comparator | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| T-Diet plus Diabet IR | Dietary Supplement | Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 1 | The variables recorded related to glycemic control in mg/dL are provided in this table. | 28 days post-admission |
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 2 | The variables recorded related to administered insulin in IU/day are provided in this table | 28 days post-admission |
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 3 | The variables recorded related to number of capillary glycemia measurements are provided in this table | 28 days post-admission |
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 4 | The variables recorded related to the number of measurements per patient per day are provided in this table | 28 days post-admission |
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 5 | The variables recorded related to Glycemic CV (%) are provided in this table:
| 28 days post-admission |
| Primary Outcome: Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.1 | This table shows the number of capillary glycemia measurements | 28 days post-admission |
| Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.2 |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of Critical Ill Patients Progress During Hospital Stay 1 | Infectious complication incidence rate per 100 days of treatment are provided in this table. | 100 days of treatment |
| Assessment of Critical Ill Patients Progress During Hospital Stay 2 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients with a life expectancy less than 48 hours.
Patients participating in another study.
Patients with APACHE II (Acute Physiology and Chronic Health Evaluation) less than 10.
Patients with BMI (body mass index) > 40 Kg/m2.
Patients with Type I Diabetes.
Patients on chronic treatment with corticosteroid dose above 1 mg / kg / day of methylprednisolone or equivalent.
Pregnant patients.
Patients taking lipid-lowering drugs.
Acute renal failure patients, defined by the following criteria:
Hepatic failure patients, defined by the following parameters:
Patients with parenteral nutrition during study inclusion.
Informed consent absence.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alfonso Mesejo, PhD | Hospital Clinico Universitario de Valencia | Principal Investigator |
| Juan Carlos Montejo, PhD | Hospital Universitario 12 de Octubre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Intensive Care Unit. Hospital Universitario 12 de Octubre | Madrid | Madrid | Spain | |||
| Intensive Care Unit. Hospital Clinico Universitario de Valencia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26549276 | Derived | Mesejo A, Montejo-Gonzalez JC, Vaquerizo-Alonso C, Lobo-Tamer G, Zabarte-Martinez M, Herrero-Meseguer JI, Acosta-Escribano J, Blesa-Malpica A, Martinez-Lozano F. Diabetes-specific enteral nutrition formula in hyperglycemic, mechanically ventilated, critically ill patients: a prospective, open-label, blind-randomized, multicenter study. Crit Care. 2015 Nov 9;19:390. doi: 10.1186/s13054-015-1108-1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was performed over the period April 2010 to May 2012. A website was constructed to record data and to randoize patients to each EN formula. Data were collected online using an electronic case report form.
This study examines whether a high-protein diabetes-specific formula reduces insulin needs, improves glycemic control and reduces ICU-adquired infection in critically ill, hyperglycemic patients on mechanical ventilation (MV)
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | DIABA HP | Patients of this group received Diaba HP as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition. DIABA HP group received, 25 kcal / kg /day for 28 days, via gastric or transpyloric. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ISOSOURCE PROTEIN FIBRE | Dietary Supplement | Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| GLUCERNA SELECT | Dietary Supplement | Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
This table shows the rates of:
|
| 28 days post-admission |
Number of participants with catheter-associated bloodstream infection, primary bloodstream infection or urinary tract infection are provided in this table |
| 28 days post-admission |
| Assessment of Critical Ill Patients Progress During Hospital Stay 3 | The incidence of tracheobronchitis and ventilator-associated pneumonia per 1000 days of mechanical ventilation are provided in this table. | 28 days post-admission |
| Assessment of Critical Ill Patients Progress During Hospital Stay 4 | Number of participants with infectious complications is provided in this table. | 100 days of treatment |
| Valencia |
| Valencia |
| Spain |
| FG001 | ISOSOURCE PROTEIN FIBRE | Patients of this group received ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture. ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric. |
| FG002 | GLUCERNA SELECT | Patients of this group received GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group will received 25 kcal / kg / day for 28 days, via gastric or transpyloric. |
| COMPLETED |
|
| NOT COMPLETED |
|
Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | DIABA HP | Patients of this group received new-generation diabetes-specific high-protein formula (Diaba HP®, Vegenat, Badajoz, Spain); as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric Diaba HP: Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition. DIABA HP group received, 25 kcal / kg/ day for 28 days, via gastric or transpyloric. |
| BG001 | ISOSOURCE PROTEIN FIBRE | Patients of this group will received ISOSOURCE PROTEIN FIBRE (Nestlé Health Science, barcelona, Spain) as unique nutritional support throughout the day, receiving 25 kcal / kg /day (from the first 48 hours after checking tolerance) via gastric or transpyloric ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture. ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric. |
| BG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Nutrition, Madrid, Spain) as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group received 25 kcal / kg / day for 28 days, via gastric or transpyloric. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Inter-Quartile Range | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Body Mass Index (BMI) | Median | Inter-Quartile Range | kg/m^2 |
| |||||||||||||||
| APACHE II | Acute Physiology and Chronic Health Evaluation II Scale: 0 to 71: based on several measures: at higher score, more severe illness and greater risk of death. | Median | Inter-Quartile Range | units on a scale |
| ||||||||||||||
| SOFA score | Sepsis-related Organ Failure Assessment score. Score: 0-6: 10% of mortality; 7-9: 15-20% of mortality; 10-12: 40-50% of mortality; 13-14: 50-60 % of mortality; 15: >80% of mortality; 16-24: >90% of mortality. | Median | Inter-Quartile Range | units on a scale |
| ||||||||||||||
| Calorie requirements | Geometric Mean | Standard Deviation | kcal/day |
| |||||||||||||||
| Start of EN | Start of Enteral Nutrition: elapsed time from admission to start enteral nutrition | Median | Inter-Quartile Range | hours |
| ||||||||||||||
| Noninsulin-dependent diabetes | Number | participants |
| ||||||||||||||||
| HbA1c | Mean | Standard Deviation | percentaje of glycated hemoglobin |
| |||||||||||||||
| Capillary glucose level | Measured after fasting and without insulin infusion for at least 8 hours | Mean | Standard Deviation | mg/dL |
| ||||||||||||||
| Plasma glucose level | Measured after fasting and without insulin infusion for at least 8 hours | Mean | Standard Deviation | mg/dL |
| ||||||||||||||
| Insulinemia | Measured after fasting and without insulin infusion for at least 8 hours | Mean | Standard Deviation | microU/mL |
| ||||||||||||||
| C-peptide | Measured after fasting and without insulin infusion for at least 8 hours | Mean | Standard Deviation | ng/mL |
| ||||||||||||||
| HOMA2 IR | HOMA 2: Homeostasis Model Assessment IR: Insulin Resistance. Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations. The HOMA model compares favorably with other models and has the advantage of requiring only a single plasma sample assayed for insulin and glucose. Higher values represent higher insulinemia. | Mean | Standard Deviation | units on a scale |
| ||||||||||||||
| HOMA2 %B | HOMA 2: Homeostasis Model Assessment B: Beta cell function. Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations. | Mean | Standard Deviation | % of beta cell function |
| ||||||||||||||
| HOMA2 %S | HOMA2: Homeostasis Model Assessment S: Insulin Sensitivity | Mean | Standard Deviation | % of insulin sensitivity |
| ||||||||||||||
| Infection | Number of patients with infection from any source | Number | participants |
| |||||||||||||||
| Diagnostic group: Medical | Number | participants |
| ||||||||||||||||
| Diagnostic group: Trauma | Number | participants |
| ||||||||||||||||
| Diagnostic group: Surgery | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 1 | The variables recorded related to glycemic control in mg/dL are provided in this table. | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Mean | Standard Deviation | mg/dL | 28 days post-admission |
|
|
| ||||||||||||||||||||||||||||||||
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 2 | The variables recorded related to administered insulin in IU/day are provided in this table | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Mean | Standard Deviation | IU/day | 28 days post-admission |
| ||||||||||||||||||||||||||||||||||
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 3 | The variables recorded related to number of capillary glycemia measurements are provided in this table | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | Capillary glycemia measurements | 28 days post-admission |
| |||||||||||||||||||||||||||||||||||
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 4 | The variables recorded related to the number of measurements per patient per day are provided in this table | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Mean | Standard Deviation | Measurements per patient/day | 28 days post-admission |
| ||||||||||||||||||||||||||||||||||
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 5 | The variables recorded related to Glycemic CV (%) are provided in this table:
| Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Mean | Standard Deviation | percentage of Glycemic CV | 28 days post-admission |
| ||||||||||||||||||||||||||||||||||
| Primary | Primary Outcome: Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.1 | This table shows the number of capillary glycemia measurements | Posted | Number | number of capillary glycemia measurement | 28 days post-admission |
| ||||||||||||||||||||||||||||||||||||
| Primary | Measure of Biochemical Parameters and Evaluation of Infectious Complications 6.2 | This table shows the rates of:
| Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | % of capillary glycemia measurements | 28 days post-admission |
| |||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Critical Ill Patients Progress During Hospital Stay 1 | Infectious complication incidence rate per 100 days of treatment are provided in this table. | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | percentage of patients with infection | 100 days of treatment |
| |||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Critical Ill Patients Progress During Hospital Stay 2 | Number of participants with catheter-associated bloodstream infection, primary bloodstream infection or urinary tract infection are provided in this table | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | participants | 28 days post-admission |
| |||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Critical Ill Patients Progress During Hospital Stay 3 | The incidence of tracheobronchitis and ventilator-associated pneumonia per 1000 days of mechanical ventilation are provided in this table. | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | number of new cases per 1000 days | 28 days post-admission |
| |||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Critical Ill Patients Progress During Hospital Stay 4 | Number of participants with infectious complications is provided in this table. | Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission. | Posted | Number | participants | 100 days of treatment |
|
All participants were followed at the ICU for a maximum of 28 days.
No adverse effects have been observed and/or registered related with the products intake during the clinical trial period. Data provided in outcome measure are related with the individual patology of each patient, not with the product intake (enteral nutrition intake).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | DIABA HP | Patients of this group received Diaba HP® as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric Diaba HP is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition. DIABA HP group received, 25 kcal / kg /day for 28 days, via gastric or transpyloric. | 0 | 52 | 0 | 52 | ||
| EG001 | ISOSOURCE PROTEIN FIBRE | Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day, receiving 25 kcal / kg / day (from the first 48 hours after checking tolerance) via gastric or transpyloric ISOSOURCE PROTEIN FIBRE: Isosource protein fibre is a complete high protein diet with fibre mixture. ISOSOURCE PROTEIN FIBRE group received, 25 kcal / kg / day for 28 days, via gastric or transpyloric. | 0 | 53 | 0 | 53 | ||
| EG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg/ day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group will receive 25 kcal / kg / day for 28 days, via gastric or transpyloric. | 0 | 52 | 0 | 52 |
Not provided
Not provided
No overall limitations and caveats have been observed and/or registered related with the products intake during the clinical trial period.
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Alfonso Mesejo | Intensive Care Unit, Hospital Clínico Universitario | 961 97 35 00 | mesejo_alf@gva.es |
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D006943 | Hyperglycemia |
| D044342 | Malnutrition |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D009748 | Nutrition Disorders |
| D006946 | Hyperinsulinism |
Not provided
Not provided
| ID | Term |
|---|---|
| D010645 | Phentermine |
| ID | Term |
|---|---|
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
Not provided
Not provided
| Male |
|
|
| Mean capillary glycemia on ICU day 1 (mg/dL) |
|
| Peak glucose level (mg/dL) |
|
| Glycemic variability SD (mg/dL) (ICU days 1-28) |
|
| Glycemic variability SD (mg/dL) (ICU days 1-7) |
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. GLUCERNA SELECT group will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|
| OG002 | GLUCERNA SELECT | Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric GLUCERNA SELECT: Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates. Group GLUCERNA SELECT will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric. |
|
|